IRVINE, Calif., Aug. 19 /PRNewswire-FirstCall/ -- Masimo (Nasdaq: MASI), the inventor of Masimo rainbow® Pulse CO-Oximetry™, Masimo rainbow Acoustic Monitoring™, and Masimo SET® Measure-Through Motion and Low Perfusion pulse oximetry, announces an expanded supplier agreement that adds Masimo rainbow Pulse CO-Oximetry and patient monitoring solutions to the purchasing contract with Premier Purchasing Partners, LP, the group purchasing unit of Premier, Inc. Now, in addition to Masimo SET pulse oximetry solutions, members of Premier, a leading national healthcare group purchasing organization, will be able to directly access and purchase the complete market-leading line of Masimo rainbow Pulse CO-Oximeters and sensors at significant contracted savings.
Effective August 1, 2010, through May 31, 2012, Premier members can purchase Masimo standalone (Radical-7®, Rad-87®) and portable (Rad-57®, Pronto-7™) rainbow Pulse CO-Oximeters on contract, along with ReSposable, adhesive/disposable, and reusable sensors for all categories of patients (from neonatal and infant/pediatric to adult).
With Masimo rainbow Pulse CO-Oximeters, clinicians can noninvasively and continuously measure many blood constituents that previously required invasive procedures, including: hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), Pleth Variability Index (PVI®), and acoustic respiration rate (RRa™), in addition to the gold-standard performance of Measure-Through Motion and Low Perfusion Masimo SET® oxyhemoglobin (SpO2), perfusion index (PI), and pulse rate. Featuring revolutionary rainbow technology, these advanced patient monitors provide continuous measurements of critical physiological parameters with real-time tracking and trending capabilities that help clinicians to identify abnormalities and patient deterioration sooner—facilitating earlier detection and treatment of potentially life-threatening conditions.
And, as the only upgradeable oximetry technology platform enabling new device capabilities to be added through simple field-installed software upgrades, Masimo rainbow Pulse CO-Oximeters allow healthcare facilities to fight the rising costs of equipment obsolescence. Instead of costly device and hardware replacements, new noninvasive measurements and patient monitoring capabilities can be cost-effectively added to existing "rainbow-ready" Masimo oximeters via a quick and easy field-installed software upgrader tool.
Masimo Founder & CEO, Joe Kiani, stated, "Masimo rainbow Pulse CO-Oximeters provide clinicians with breakthrough noninvasive measurements and physiological information they've never before had continuous, real-time access to. Armed with this level of clinical detail allows clinicians to improve and reduce the cost of care."
About the Premier Healthcare AlliancePremier is a performance improvement alliance of more than 2,400 U.S. hospitals and nearly 70,000 other healthcare sites working together to achieve high quality, cost-effective care. Owned by not-for-profit hospitals, Premier maintains the nation's most comprehensive repository of clinical, financial and outcomes information and operates a leading healthcare purchasing network. A world leader in helping deliver measurable improvements in care, Premier works with the Centers for Medicare & Medicaid Services and the United Kingdom's National Health Service North West to improve hospital performance. Headquartered in Charlotte, N.C., Premier also has offices in San Diego, Philadelphia and Washington. http://www.premierinc.com.
About MasimoMasimo (NASDAQ: MASI) develops innovative monitoring technologies that significantly improve patient care—helping solve "unsolvable" problems. In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. More than 100 independent and objective studies demonstrate Masimo SET provides the most reliable SpO2 and pulse rate measurements even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced rainbow® Pulse CO-Oximetry™, allowing noninvasive and continuous monitoring of blood constituents that previously required invasive procedures, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and Pleth Variability Index (PVI®), in addition to SpO2, pulse rate, and perfusion index (PI). In 2009, Masimo introduced rainbow Acoustic Monitoring™, the first-ever noninvasive and continuous monitoring of acoustic respiration rate (RRa™). Masimo's rainbow platform offers a breakthrough in patient safety by helping clinicians detect life-threatening conditions and helping guide treatment options. Founded in 1989, Masimo has the mission of "Improving Patient Outcome and Reducing Cost of Care … by Taking Noninvasive Monitoring to New Sites and Applications®." Additional information about Masimo and its products may be found at www.masimo.com.
Forward Looking StatementsThis press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our belief that the specificity and sensitivity of Masimo rainbow Pulse CO-Oximetry technology will provide continuous measurements of critical physiological parameters with real-time tracking and trending capabilities in all patients; risks related to the assumption that continuous Pulse CO-Oximetry measurements will enable clinicians to identify patient deterioration sooner and facilitate earlier detection and treatment of potentially life-threatening conditions, as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these forward-looking statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.Media Contacts:Dana BanksMasimo Corporation(949) email@example.comMasimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care… by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO, SpMet, PVI, rainbow Acoustic Monitoring, RRa, Radical-7, Rad-87, Rad-57,Rad-8, Rad-5,Pulse CO-Oximetry, Pulse CO-Oximeter, and SEDLine are trademarks or registered trademarks of Masimo Corporation.
Copyright©2010 PR Newswire.
All rights reserved